20:07 , Aug 16, 2017 |  BC Week In Review  |  Clinical News

Amylyx begins Phase II of AMX0035 for ALS

Amylyx Pharmaceutical Corp. (Cambridge, Mass.) began the Phase II CENTAUR trial to evaluate twice-daily oral AMX0035 for 24 weeks in 132 patients with amyotrophic lateral sclerosis (ALS). The double-blind, placebo-controlled, U.S. trial will evaluate the primary...
20:12 , Jul 7, 2017 |  BC Week In Review  |  Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit...
22:11 , Jul 3, 2017 |  BC Extra  |  Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Company News

Hyperion Therapeutics Inc, Horizon Pharma deal

Last June, EMA accepted for review an MAA for Ravicti to treat UCD; Hyperion expects a decision from EMA’s CHMP in late 2015 or early 2016. Hyperion plans to submit an sNDA for Ravicti to...
01:06 , Mar 31, 2015 |  BC Extra  |  Company News

Horizon buying Hyperion for $1.1B

Horizon Pharma plc (NASDAQ:HZNP) will acquire rare disease company Hyperion Therapeutics Inc. (NASDAQ:HPTX) for $46 per share, or $1.1 billion in cash. The price represents an 8% premium to Hyperion's Friday close of $42.74. Horizon...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

Pheburane sodium phenylbutyrate regulatory update

The Medunik Canada subsidiary of Le Groupe Pharmaceutique Boivin (Montreal, Quebec) said Health Canada approved Pheburane sodium phenylbutyrate as adjunctive therapy in the chronic management of urea cycle disorders (UCD). The company has exclusive...
07:00 , Jun 5, 2014 |  BC Innovations  |  Targets & Mechanisms

De-stressing glaucoma

Glucocorticoids are standard of care for a host of allergic and inflammatory eye conditions, but they elevate intraocular pressure about a third of the time and can result in secondary open-angle glaucoma. A chemical chaperone...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

Ravicti glycerol phenylbutyrate: Postmarketing study started

Hyperion began the THRIVE patient registry study to evaluate standard of care treatments, including ammonia-scavenging agents Ravicti, sodium phenylbutyrate or sodium benzoate, in up to 500 patients with UCD for up to 10 years. FDA...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

Hyperion, Valeant Pharmaceuticals deal

Hyperion completed the acquisition of worldwide rights to Buphenyl sodium phenylbutyrate from Valeant's Ucyclyd Pharma Inc. subsidiary. The exercise price was $19 million. The subsidiary exercised its option to retain Ammonul for $32 million....
07:00 , May 13, 2013 |  BC Week In Review  |  Company News

Hyperion, Valeant Pharmaceuticals deal

Hyperion exercised its option under an amended 2007 deal with Valeant's Medicis Pharmaceutical Corp. subsidiary to acquire worldwide rights to Buphenyl sodium phenylbutyrate and Ammonul. Hyperion will pay $22 million up front to...